• 1
    Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167: 17341739.
  • 2
    Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360: 4753.
  • 3
    Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101: 747754.
  • 4
    Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999;104: 364369.
  • 5
    Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115: 12651270.
  • 6
    Khan LN, Kon OM, Macfarlane AJ, Meng Q, Ying S, Barnes NC et al. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, IL-5, GM-CSF and eotaxin. Am J Respir Crit Care Med 2000;162: 13771382.
  • 7
    Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T-cells of patients allergic to cats. J Allergy Clin Immunol 1998;102: 571578.
  • 8
    Apostolou I, Von Boehmer H. In vivo instruction of suppressor commitment in naive T-cells. J Exp Med 2004;199: 14011408.
  • 9
    Alexander C, Oldfield WL, Shirley K, Larche M, Kay AB. A dosing protocol of allergen-derived T cell peptide epitopes for the treatment of allergic disease. J Allergy Clin Immunol 2001;107: 716 abs.
  • 10
    Smith TRF, Alexander C, Kay AB, Larché M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+CD25+ T cells: double-blind placebo-controlled study. Allergy 2004;59: 10971101.
  • 11
    Verhoef A, Alexander C, Kay AB, Larche M. Allergen-based peptide immunotherapy is associated with functional modifications in allergen-specific T cell subpopulations. J Allergy Clin Immunol 2004;113: S255.
  • 12
    Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189: 18851894.